Startup profile for GC Therapeutics: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

GC Therapeutics funding, valuation and investors

Cell-therapy biotech using George Church–originated iPSC programming platform TFome.

Verified company research · funding, investors and latest developments

Keep track of GC Therapeutics

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$65M · 2024

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$65M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Cambridge, Massachusetts

Investors in latest funding

Lead: Cormorant Asset Management

Other: Andreessen Horowitz , Pear VC

Sources: latest funding · businesswire.com Last verified: 2026-07-25

Overview

GC Therapeutics (GCTx) develops off-the-shelf cell therapies using TFome, a proprietary iPSC programming platform originated from George Church's lab — aiming to manufacture consistent cell products at scale.

Why GC Therapeutics is interesting

GC Therapeutics targets scalable off-the-shelf cell therapies; a16z Bio + Health joined Pear VC in its $65M Series A launch round.

Product & use cases

GC Therapeutics (GCTx) uses TFome, an iPSC programming platform from George Church's lab, to manufacture off-the-shelf cell therapies at scale.

  • Off-the-shelf regenerative cell products
  • Consistent iPSC-derived therapies vs. autologous manufacturing
  • Platform licensing for cell therapy developers

Key facts

  • Series A (2024): $65M led by Cormorant Asset Management with a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) (BusinessWire)
  • TFome platform originated from George Church's lab at Harvard; targets scalable off-the-shelf iPSC cell therapies

Funding history (newest first)

Investors in our directory

Funds linked from GC Therapeutics's profile — open a fund page for stage focus and related deal articles.

Competitive landscape

Edge: TFome platform originated in George Church's Harvard lab — targets manufacturing consistency that autologous cell therapy lacks.

Off-the-shelf cell therapy is a crowded thesis; GCTx bets TFome programming from Church lab IP delivers repeatable products. Clinical validation still ahead.

  • Fate Therapeutics direct

    iPSC-derived cell therapies; GCTx differentiates on TFome programming.

  • Century Therapeutics direct

    iPSC NK/T cell programs; overlapping off-the-shelf thesis.

  • Autologous CAR-T makers alternative

    Patient-specific manufacturing; higher cost, harder scale.

Notable stories

  • TFome platform originated from George Church's lab at Harvard (BusinessWire, 2024).
  • Launched with $65M Series A to advance off-the-shelf iPSC cell therapies.

Industries

Market / IPO context

Editorial / static context — not a live quote.

FAQs about GC Therapeutics

Practical answers founders, operators, and investors typically search for.

GC Therapeutics develops off-the-shelf cell therapies using TFome, an iPSC programming platform from George Church's lab.
Cormorant led the $65M Series A (2024). a16z Bio + Health (/fund/andreessen-horowitz) and Pear VC (/fund/pear-vc) participated.
GC Therapeutics' proprietary iPSC programming platform for consistent, scalable cell product manufacturing.
Autologous uses patient cells; GCTx targets off-the-shelf iPSC products for lower cost and faster delivery.
Series A — $65M launch round in 2024.
The company emerged from George Church's lab research on iPSC programming.
Cambridge, Massachusetts per company materials.
Manufacturing consistency is the bottleneck for scalable cell therapy — TFome targets repeatable programming.
No — remains private.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.